23.2.2020 19:24:26 Marika Letní
Remdesivir
Tady ještě podrobnosti ze stránek Gileadu. Výsledky 2 studií probíhajících v Číně budou známy v dubnu. Jedna studie s lidmi potřebujícími dechovou podporu, druhá s těmi ve vážném stavu bez nutnosti dechové podpory.
"Clinical Trials
Together with health authorities in China, Gilead has initiated two clinical trials in patients who have been infected with COVID-19 to determine the safety and efficacy of remdesivir as a potential treatment for the coronavirus. The two studies are being coordinated by the China-Japan Friendship Hospital and are being conducted at multiple sites in Hubei province. Gilead is providing study drug at no charge and provided input on study design and conduct.
One study is evaluating remdesivir in patients with confirmed disease who have developed more severe clinical manifestations such as a requirement for supplemental oxygen. The other study is evaluating remdesivir in patients with confirmed COVID-19 infection who have been hospitalized but are not displaying significant clinical manifestations of disease such as an oxygen requirement. The study in patients with severe disease began enrolling patients on February 6. The study in patients with moderate disease began enrolling patients on February 13. Clinical trial results are anticipated in April."
Gilead poskytl léky pro studie a Čínani se s tím opět nemažou, jak je jejich zvykem, a rozjeli výrobu bez ohledu na licenci.
https://time.com/5782633/covid-19-drug-remdesivir-china/
Odpovědět